|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
125,280,000 |
Market
Cap: |
5.48(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.16 - $47.08 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 20.8 |
Insider 6 Months : 24.2 |
Insider 3/6 Months : 45.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Corbus Pharmaceuticals Holdings is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Co.'s pipeline includes anti-integrin monoclonal antibodies that block activation of Transforming growth factor B (TGFB) and small molecules that activate or inhibit the endocannabinoid system. Co.'s pipeline includes: anti-integrin monoclonal antibodies for the treatment of cancer and fibrosis that inhibit the activation of TGFB; cannabinoid receptor type 1 inverse agonists designed to treat obesity and related metabolic diseases; and lenabasum, a synthetic, oral molecule that activates cannabinoid receptor type 2.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
550,000 |
1,582,632 |
1,582,632 |
1,633,932 |
Total Buy Value |
$23,327,560 |
$46,689,501 |
$46,689,501 |
$46,703,200 |
Total People Bought |
1 |
2 |
2 |
5 |
Total Buy Transactions |
2 |
4 |
4 |
9 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cohen Yuval |
Chief Executive Officer |
|
2020-11-11 |
4 |
B |
$1.21 |
$5,126 |
D/D |
4,240 |
75,330 |
2.81 |
65% |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2020-03-17 |
4 |
B |
$4.25 |
$8,500 |
D/D |
2,000 |
12,000 |
2.74 |
71% |
|
Discordia Robert Paul |
Chief Operating Officer |
|
2020-03-17 |
4 |
B |
$3.54 |
$10,054 |
D/D |
2,840 |
35,490 |
2.74 |
71% |
|
White Barbara |
Chief Medical Officer |
|
2020-03-17 |
4 |
B |
$3.63 |
$56,650 |
D/D |
15,606 |
206,217 |
2.74 |
71% |
|
Cohen Yuval |
Chief Executive Officer |
|
2020-03-17 |
4 |
B |
$3.49 |
$15,007 |
D/D |
4,300 |
71,090 |
2.81 |
71% |
|
White Barbara |
Chief Medical Officer |
|
2019-11-12 |
4 |
B |
$4.38 |
$14,992 |
D/D |
3,424 |
190,611 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2019-11-12 |
4 |
B |
$4.26 |
$6,092 |
D/D |
1,430 |
66,790 |
2.81 |
- |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2019-11-11 |
4 |
B |
$4.38 |
$4,380 |
D/D |
1,000 |
10,000 |
2.66 |
- |
|
Discordia Robert Paul |
Chief Operating Officer |
|
2019-11-11 |
4 |
B |
$4.62 |
$11,559 |
D/D |
2,500 |
32,650 |
2.74 |
- |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2019-08-15 |
4 |
B |
$5.48 |
$8,213 |
D/D |
1,500 |
9,000 |
2.74 |
- |
|
White Barbara |
Chief Medical Officer |
|
2019-08-12 |
4 |
B |
$6.10 |
$9,998 |
D/D |
1,639 |
187,187 |
2.74 |
- |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2019-08-12 |
4 |
B |
$6.00 |
$9,000 |
D/D |
1,500 |
7,500 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2019-08-12 |
4 |
B |
$6.06 |
$7,116 |
D/D |
1,175 |
65,360 |
2.81 |
- |
|
Discordia Robert Paul |
Chief Operating Officer |
|
2019-08-12 |
4 |
B |
$5.86 |
$87,894 |
D/D |
15,000 |
30,150 |
2.74 |
- |
|
Discordia Robert Paul |
Chief Operating OfficerOfficer |
|
2019-08-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,150 |
|
- |
|
White Barbara |
Chief Medical Officer |
|
2019-05-17 |
4 |
B |
$7.20 |
$10,001 |
D/D |
1,389 |
185,548 |
2.74 |
- |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2019-05-14 |
4 |
B |
$7.23 |
$7,227 |
D/D |
1,000 |
6,000 |
2.74 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2019-05-14 |
4 |
B |
$7.12 |
$712 |
D/D |
100 |
349,610 |
2.66 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2019-05-13 |
4 |
B |
$6.99 |
$6,955 |
D/D |
995 |
64,185 |
2.81 |
- |
|
Hochman David P |
Director |
|
2019-03-15 |
4 |
B |
$6.98 |
$13,958 |
I/I |
2,000 |
7,000 |
2.1 |
- |
|
Jenkins John Kenneth |
Director |
|
2019-03-15 |
4 |
B |
$6.98 |
$6,978 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
Millian Craig Stuart |
Chief Commercial Officer |
|
2019-03-14 |
4 |
B |
$6.85 |
$34,259 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
White Barbara |
Chief Medical Officer |
|
2019-03-14 |
4 |
B |
$6.47 |
$29,994 |
D/D |
4,638 |
184,159 |
2.74 |
- |
|
Moran Sean F. |
Chief Financial Officer |
|
2019-03-14 |
4 |
B |
$6.67 |
$10,005 |
D/D |
1,500 |
349,510 |
2.74 |
- |
|
Cohen Yuval |
Chief Executive Officer |
|
2019-03-14 |
4 |
B |
$6.49 |
$9,930 |
D/D |
1,530 |
63,190 |
2.81 |
- |
|
176 Records found
|
|
Page 2 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|